Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights

SG&A Expenses: Veracyte vs. Taro - A Decade of Change

__timestampTaro Pharmaceutical Industries Ltd.Veracyte, Inc.
Wednesday, January 1, 20149173300040786000
Thursday, January 1, 20158764400047876000
Friday, January 1, 20169236500052035000
Sunday, January 1, 20178565600055348000
Monday, January 1, 20188819600065276000
Tuesday, January 1, 20198997100082720000
Wednesday, January 1, 20209341300089118000
Friday, January 1, 202191355000181193000
Saturday, January 1, 2022113676000174078000
Sunday, January 1, 2023198366000184232000
Monday, January 1, 2024218935000
Loading chart...

Cracking the code

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Veracyte, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro's SG&A expenses have shown a steady increase, peaking at approximately 218% of their 2014 value by 2023. In contrast, Veracyte's expenses surged dramatically, reaching nearly 452% of their 2014 levels by 2022, before data became unavailable in 2023. This trend highlights Veracyte's aggressive expansion strategy, while Taro maintains a more conservative growth approach. The absence of Veracyte's 2024 data suggests a potential shift or reevaluation in their financial strategy. Investors and industry analysts should consider these trends when evaluating the companies' future growth and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025